VWF release and platelet aggregation in human melanoma after perfusion with TNFα

The Journal of Pathology

Volumn 176, Issue 3, 1995, Pages 279-287

  Renard, Nathalie ^a,d   Nooijen, Peet T G A ^b,d   Schalkwijk, Lia ^b,d   De Waal, Robert M W ^b,d   Eggermont, Alexander M M ^c,d   Liénard, Danielle ^a,d   Kroon, Bin B R ^d,e   Lejeune, Ferdy J ^a,d   Ruiter, Dirk J ^b,d  

^a JULES BORDET INSTITUTE   (Belgium)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

CD41 and thrombocytes; isolated limb perfusion; melanoma; TNF ; VWF

Indexed keywords

GAMMA INTERFERON; MELPHALAN; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; VON WILLEBRAND FACTOR;

ARTICLE; CLINICAL ARTICLE; COMPLICATION; ETIOLOGY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIMB PERFUSION; MELANOMA; PRIORITY JOURNAL; SIDE EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE AGGREGATION;

COMBINED MODALITY THERAPY; HUMAN; INTERFERON-GAMMA, RECOMBINANT; MELANOMA; MELPHALAN; PERFUSION, REGIONAL; PLATELET AGGREGATION; RECOMBINANT PROTEINS; SKIN NEOPLASMS; SUPPORT, NON-U.S. GOV'T; TUMOR NECROSIS FACTOR; VON WILLEBRAND FACTOR;

EID: 0029144112     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.1711760310     Document Type: Article

References (27)

1. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high dose tumor necrosis factor alpha (rHuTNFα)
2. An endotoxin induced serum factor that causes necrosis of tumors
3. Recombinant human tumor necrosis factor administered as a 24 h intravenous infusion. A phase I and pharmacologic study
4. Studies of the antitumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo
5. High‐dose recombinant tumor necrosis factor‐alpha in combination with interferon‐gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma
6. Synergistic antitumor effects of TNFα and gamma‐IFN on human colon carcinoma cell lines
7. Modulation of endothelial cell hemostatic properties by tumor necrosis factor
8. Limb salvage by isolated limb perfusion of the limbs with high dose TNFα, gamma interferon and melphalan for stage III melanoma and irresectable soft tissue sarcomas of the extremities
9. Monoclonal antibody defined human endothelial antigens as vascular markers
10. Von Willebrand factor as a marker of injury to the endothelium in inflammatory vascular disease (Editorial)
11. Von Willebrand factor and the endothelium in vascular disease
12. Organization of von Willebrand factor on surface‐activated platelets
13. Haemolytic‐uraemic syndrome basic science
14. TNF‐induced microvascular pathology‐active role for platelets and importance of the LFA‐ICAM‐interactions
15. Differential regulation by cytokines of constitutive and stimulated secretion of von Willebrand factor from endothelial cells
16. Tumor necrosis factor induces von Willebrand factor release in healthy humans
17. The role of tissue factor in the production of thrombin
18. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium; characterization and comparison with the actions of interleukin‐l
19. Monoclonal antibody PAL‐E specific for endothelium
20. Smooth muscle α‐actin is a transformation‐sensitive marker for mouse NIH 3t3 and Rat‐2 cells
21. Tissue factor as a tumor procoagulant
22. A monoclonal antibody specific for cells of the melanocyte lineage
23. Handbook of immunoprecipitations in gel techniques
24. Immunocytochemical detection of basement membrane antigens in the histopathological evaluation of laryngeal dysplasia and neoplasia
25. A monoclonal antibody‐based enzyme immunoassay for fibrin degradation products in plasma